Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-NCS-2
- Development stage
- Preclinical
- Lead developer
- GlycosBio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
GB-NCS-2 is a lipid-engineered nutraceutical candidate developed by GlycosBio for the management of renal disorders. It utilizes the company's proprietary Activated Oil System technology, which is designed to enhance the bioavailability and targeted delivery of nutritional lipids. As a functional food or medical nutrition product, GB-NCS-2 aims to support renal health through nutritional intervention rather than traditional molecular pharmacology. It is currently in clinical development as part of GlycosBio's nutrition-focused pipeline.
Beyond the preview
Go deeper on GB-NCS-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-NCS-2.